Albiruni Abdul Razak

机构：Princess Margaret Cancer Centre

发表论文 64 篇 · 总被引 2029 次 · h-index 20

代表论文

• Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab (2020 · Nature Cancer · 被引 503)
• Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities (2019 · Cancer · 被引 144)
• Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity (2021 · Nature Communications · 被引 130)
• Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study (2022 · Annals of Oncology · 被引 85)
• Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2024 · The Lancet · 被引 79)
• An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors (2020 · Journal for ImmunoTherapy of Cancer · 被引 70)